Europe may see a profitable expansion in the global pulmonary edoema therapeutics market over the forecast period as a result of increased collaborations and sales partnerships. For example, Novartis International AG, a leading pharmaceutical company, announced on November 19, 2020, an exclusive global licence and collaboration agreement with Mesoblast to develop, commercialise, and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.
Remestemcel-L is an experimental therapy that comprises of culture-expanded mesenchymal stromal cells taken from the bone marrow of an unrelated donor.
Read more:
https://knackersblogger.blogspot.com/2022/09/pulmonary-edema-therapeutics-market_23.html
